Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 245Nivolumab 141Cisplatin 137Cyclophosphamide 134Paclitaxel 115Carboplatin 108Gemcitabine 98Radiotherapy 84Dexamethasone 83Docetaxel 77atezolizumab 69Ipilimumab 67Fluorouracil 61Doxorubicin 61Blood Specimen Collection 59Bevacizumab 59Rituximab 55fludarabine 54Etoposide 53Oxaliplatin 52Lenalidomide 50Surveys and Questionnaires 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Radiosurgery 44Cetuximab 44lenvatinib 43Capecitabine 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ASTX029 × 1 year × Clear all
NCT03520075 2025-07-03

Study of ASTX029 in Subjects With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
192 enrolled 56 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡